Response to Comments: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin (DL39477)

This response-to-comments article concerns allogeneic hematopoietic cell transplantation for patients with primary refractory or relapsed Hodgkin lymphoma or non-Hodgkin lymphoma of B- or T-cell origin. The provided text does not include specific coverage criteria, documentation requirements, limitations, or frequency limits; review of the full LCD is required for actionable policy details.

"Allogeneic hematopoietic cell transplantation (HCT) for patients with primary refractory or relapsed Hodgkin lymphoma or non-Hodgkin lymphoma of B-cell or T-cell origin."

Sign up to see full coverage criteria, indications, and limitations.